2ky6: Difference between revisions

No edit summary
No edit summary
 
Line 4: Line 4:
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[2ky6]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2KY6 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2KY6 FirstGlance]. <br>
<table><tr><td colspan='2'>[[2ky6]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2KY6 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2KY6 FirstGlance]. <br>
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2ky6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2ky6 OCA], [https://pdbe.org/2ky6 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2ky6 RCSB], [https://www.ebi.ac.uk/pdbsum/2ky6 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2ky6 ProSAT]</span></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2ky6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2ky6 OCA], [https://pdbe.org/2ky6 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2ky6 RCSB], [https://www.ebi.ac.uk/pdbsum/2ky6 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2ky6 ProSAT]</span></td></tr>
</table>
</table>
== Disease ==
== Disease ==
Line 10: Line 11:
== Function ==
== Function ==
[https://www.uniprot.org/uniprot/MED25_HUMAN MED25_HUMAN] Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. Required for RARA/RXRA-mediated transcription.<ref>PMID:14657022</ref> <ref>PMID:14983011</ref> <ref>PMID:17641689</ref>  
[https://www.uniprot.org/uniprot/MED25_HUMAN MED25_HUMAN] Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. Required for RARA/RXRA-mediated transcription.<ref>PMID:14657022</ref> <ref>PMID:14983011</ref> <ref>PMID:17641689</ref>  
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
The human Mediator coactivator complex interacts with many transcriptional activators and facilitates recruitment of RNA polymerase II to promote target gene transcription. The MED25 subunit is a critical target of the potent herpes simplex 1 viral transcriptional activator VP16. Here we determine the solution structure of the MED25 VP16-binding domain (VBD) and define its binding site for the N-terminal portion of the VP16 transactivation domain (TADn). A hydrophobic furrow, formed by a beta-barrel and two alpha-helices in MED25 VBD, interacts tightly with VP16 TADn. Mutations in this furrow prevent binding of VP16 TAD to MED25 VBD and interfere with the ability of overexpressed MED25 VBD to inhibit VP16-dependent transcriptional activation in vivo. This detailed molecular understanding of transactivation by the benchmark activator VP16 could provide important insights into viral and cellular gene activation mechanisms.
Structure of the VP16 transactivator target in the Mediator.,Milbradt AG, Kulkarni M, Yi T, Takeuchi K, Sun ZY, Luna RE, Selenko P, Naar AM, Wagner G Nat Struct Mol Biol. 2011 Apr;18(4):410-5. Epub 2011 Mar 6. PMID:21378963<ref>PMID:21378963</ref>
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 2ky6" style="background-color:#fffaf0;"></div>


==See Also==
==See Also==

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA